Literature DB >> 26841829

Establishment of isogenic iPSCs from an individual with SCN1A mutation mosaicism as a model for investigating neurocognitive impairment in Dravet syndrome.

Hiroshi Maeda1, Tomohiro Chiyonobu1, Michiko Yoshida1,2, Satoshi Yamashita1, Masashi Zuiki1, Satoshi Kidowaki1, Kenichi Isoda1,2, Kazuhiro Yamakawa3, Masafumi Morimoto1, Tatsutoshi Nakahata2, Megumu K Saito2, Hajime Hosoi1.   

Abstract

Dravet syndrome (DS) is a severe childhood epilepsy typically caused by de novo dominant mutations in SCN1A. Although patients with DS frequently have neurocognitive abnormalities, the precise neural mechanisms responsible for their expression have not been elucidated. There are wide phenotypic differences among individuals with SCN1A mutations, suggesting that factors other than the SCN1A mutation modify the phenotype. Therefore, a well-controlled cellular model system is required to improve our understanding of the mechanisms underlying DS. Here we generated induced pluripotent stem cell (iPSC) lines from an individual with SCN1A mutation mosaicism, and separately cloned iPSC lines both with and without the SCN1A mutation. These clones theoretically have the same genetic backgrounds, except for the SCN1A gene, and should serve as an ideal pair for investigating the pathophysiology caused by SCN1A mutations. Quantitative reverse transcription-PCR and western blot analysis revealed higher tyrosine hydroxylase mRNA and protein expression levels in mutant neurons than in wild-type neurons. Moreover, dopamine concentrations in media collected from mutant neural cultures were higher than those from wild-type neural cultures. Our findings suggest that SCN1A mutation leads to changes in the dopamine system that may contribute to the behavioral abnormalities in DS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26841829     DOI: 10.1038/jhg.2016.5

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  16 in total

1.  SCN1A mutation mosaicism in a family with severe myoclonic epilepsy in infancy.

Authors:  Masafumi Morimoto; Emi Mazaki; Akira Nishimura; Tomohiro Chiyonobu; Yasuko Sawai; Aki Murakami; Keiko Nakamura; Ikuyo Inoue; Ikuo Ogiwara; Tohru Sugimoto; Kazuhiro Yamakawa
Journal:  Epilepsia       Date:  2006-10       Impact factor: 5.864

2.  A more efficient method to generate integration-free human iPS cells.

Authors:  Keisuke Okita; Yasuko Matsumura; Yoshiko Sato; Aki Okada; Asuka Morizane; Satoshi Okamoto; Hyenjong Hong; Masato Nakagawa; Koji Tanabe; Ken-ichi Tezuka; Toshiyuki Shibata; Takahiro Kunisada; Masayo Takahashi; Jun Takahashi; Hiroh Saji; Shinya Yamanaka
Journal:  Nat Methods       Date:  2011-04-03       Impact factor: 28.547

Review 3.  Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD).

Authors:  Michael Nguyen; Andrew Roth; Evan J Kyzar; Manoj K Poudel; Keith Wong; Adam Michael Stewart; Allan V Kalueff
Journal:  Neurochem Int       Date:  2014-01-09       Impact factor: 3.921

Review 4.  Complex molecular regulation of tyrosine hydroxylase.

Authors:  Izel Tekin; Robert Roskoski; Nurgul Carkaci-Salli; Kent E Vrana
Journal:  J Neural Transm (Vienna)       Date:  2014-05-28       Impact factor: 3.575

5.  Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells.

Authors:  Asuka Morizane; Daisuke Doi; Tetsuhiro Kikuchi; Kaneyasu Nishimura; Jun Takahashi
Journal:  J Neurosci Res       Date:  2010-12-08       Impact factor: 4.164

6.  Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism.

Authors:  Yu Liu; Luis F Lopez-Santiago; Yukun Yuan; Julie M Jones; Helen Zhang; Heather A O'Malley; Gustavo A Patino; Janelle E O'Brien; Raffaella Rusconi; Ajay Gupta; Robert C Thompson; Marvin R Natowicz; Miriam H Meisler; Lori L Isom; Jack M Parent
Journal:  Ann Neurol       Date:  2013-07-02       Impact factor: 10.422

7.  Generation of the SCN1A epilepsy mutation in hiPS cells using the TALEN technique.

Authors:  Wanjuan Chen; Jingxin Liu; Longmei Zhang; Huijuan Xu; Xiaogang Guo; Sihao Deng; Lipeng Liu; Daiguan Yu; Yonglong Chen; Zhiyuan Li
Journal:  Sci Rep       Date:  2014-06-23       Impact factor: 4.379

8.  Human iPSC neurons display activity-dependent neurotransmitter secretion: aberrant catecholamine levels in schizophrenia neurons.

Authors:  Vivian Hook; Kristen J Brennand; Yongsung Kim; Thomas Toneff; Lydiane Funkelstein; Kelly C Lee; Michael Ziegler; Fred H Gage
Journal:  Stem Cell Reports       Date:  2014-09-11       Impact factor: 7.765

9.  Autistic-like behaviour in Scn1a+/- mice and rescue by enhanced GABA-mediated neurotransmission.

Authors:  Sung Han; Chao Tai; Ruth E Westenbroek; Frank H Yu; Christine S Cheah; Gregory B Potter; John L Rubenstein; Todd Scheuer; Horacio O de la Iglesia; William A Catterall
Journal:  Nature       Date:  2012-08-22       Impact factor: 49.962

10.  A human Dravet syndrome model from patient induced pluripotent stem cells.

Authors:  Norimichi Higurashi; Taku Uchida; Christoph Lossin; Yoshio Misumi; Yohei Okada; Wado Akamatsu; Yoichi Imaizumi; Bo Zhang; Kazuki Nabeshima; Masayuki X Mori; Shutaro Katsurabayashi; Yukiyoshi Shirasaka; Hideyuki Okano; Shinichi Hirose
Journal:  Mol Brain       Date:  2013-05-02       Impact factor: 4.041

View more
  8 in total

Review 1.  Integrated Genomic Medicine: A Paradigm for Rare Diseases and Beyond.

Authors:  N J Schork; K Nazor
Journal:  Adv Genet       Date:  2017-07-25       Impact factor: 1.944

2.  Modeling Pediatric Epilepsy Through iPSC-Based Technologies.

Authors:  Dina Simkin; Evangelos Kiskinis
Journal:  Epilepsy Curr       Date:  2018 Jul-Aug       Impact factor: 7.500

Review 3.  Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies.

Authors:  K R Sabitha; Ashok K Shetty; Dinesh Upadhya
Journal:  Neurosci Biobehav Rev       Date:  2020-12-25       Impact factor: 8.989

Review 4.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

Review 5.  Concise Review: Stem Cell Models of SCN1A-Related Encephalopathies-Current Perspective and Future Therapies.

Authors:  Valery Zayat; Roza Szlendak; Dorota Hoffman-Zacharska
Journal:  Cells       Date:  2022-10-04       Impact factor: 7.666

Review 6.  Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders.

Authors:  Serena Barral; Manju A Kurian
Journal:  Front Mol Neurosci       Date:  2016-09-06       Impact factor: 5.639

Review 7.  Progress in the molecular mechanisms of genetic epilepsies using patient-induced pluripotent stem cells.

Authors:  Ruijiao Zhou; Guohui Jiang; Xin Tian; Xuefeng Wang
Journal:  Epilepsia Open       Date:  2018-07-08

8.  Human neuronal networks on micro-electrode arrays are a highly robust tool to study disease-specific genotype-phenotype correlations in vitro.

Authors:  Britt Mossink; Anouk H A Verboven; Eline J H van Hugte; Teun M Klein Gunnewiek; Giulia Parodi; Katrin Linda; Chantal Schoenmaker; Tjitske Kleefstra; Tamas Kozicz; Hans van Bokhoven; Dirk Schubert; Nael Nadif Kasri; Monica Frega
Journal:  Stem Cell Reports       Date:  2021-07-29       Impact factor: 7.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.